Inhibition of corneal inflammation by the TLR4 antagonist eritoran tetrasodium (E5564)

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 3, 2009, Pages 1247-1254

  Sun, Yan ^a   Pearlman, Eric ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; ERITORAN; LIPOPOLYSACCHARIDE; PLACEBO; PROTEIN MD 2; SILICON; TOBRAMYCIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; 2,3 BIS(PALMITOYLOXY) 2 PROPYL 1 PALMITOYLCYSTEINE; 2,3-BIS(PALMITOYLOXY)-2-PROPYL-1-PALMITOYLCYSTEINE; 3 O DECYL 2 DEOXY 6 O (2 DEOXY 3 O (3 METHOXYDECYL) 6 O METHYL 2 ((1 OXO 11 OCTADECENYL)AMINO) 4 O PHOSPHONOGLUCOPYRANOSYL) 2 ((1,3 DIOXOTETRADECYL)AMINO) 1 (DIHYDROXY PHOSPHATE)GLUCOPYRANOSE; 3-O-DECYL-2-DEOXY-6-O-(2-DEOXY-3-O-(3-METHOXYDECYL)-6-O-METHYL-2-((1-OXO-11-OCTADECENYL)AMINO)-4-O-PHOSPHONOGLUCOPYRANOSYL)-2-((1,3-DIOXOTETRADECYL)AMINO)-1-(DIHYDROXY PHOSPHATE)GLUCOPYRANOSE; CXCL1 CHEMOKINE; CXCL1 PROTEIN, MOUSE; CYSTEINE; DISACCHARIDE; DRUG DERIVATIVE; LIPOPROTEIN; LY96 PROTEIN, MOUSE; SUGAR PHOSPHATE; TOLL LIKE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL INFILTRATION; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTACT LENS; CONTROLLED STUDY; CORNEA; DRUG EFFECT; HUMAN; HUMAN CELL; HYDROGEL; IMMUNOHISTOCHEMISTRY; KERATITIS; MACROPHAGE; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PSEUDOMONAS AERUGINOSA; ANIMAL; BACTERIAL EYE INFECTION; C57BL MOUSE; CORNEA EPITHELIUM; DRUG ANTAGONISM; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; MICROBIOLOGY; NICK END LABELING; PHYSIOLOGY; PSEUDOMONAS INFECTION;

ANIMALS; APOPTOSIS; CHEMOKINE CXCL1; CYSTEINE; DISACCHARIDES; EPITHELIUM, CORNEAL; EYE INFECTIONS, BACTERIAL; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; IN SITU NICK-END LABELING; KERATITIS; LIPOPOLYSACCHARIDES; LIPOPROTEINS; LYMPHOCYTE ANTIGEN 96; MACROPHAGES; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; NEUTROPHILS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SUGAR PHOSPHATES; TOLL-LIKE RECEPTORS;

EID: 62649164799     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2628     Document Type: Article

References (44)

1. Bourcier T, Thomas F, Borderie V, Chaumeil C, Laroche L. Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases. Br J Ophthalmol. 2003;87:834-838.
2. Green M, Apel A, Stapleton F. Risk factors and causative organisms in microbial keratitis. Cornea. 2008;27:22-27.
3. Stapleton F, Keay L, Jalbert I, Cole N. The epidemiology of contact lens related infiltrates. Optom Vis Sci. 2007;84:257-272.
4. Szczotka-Flynn L, Debanne SM, Cheruvu VK, et al. Predictive factors for corneal infiltrates with continuous wear of silicone hydrogel contact lenses. Arch Ophthalmol. 2007;125:488-492.
5. Holden BA, Reddy MK, Sankaridurg PR, et al. Contact lens-induced peripheral ulcers with extended wear of disposable hydrogel lenses: histopathologic observations on the nature and type of corneal infiltrate. Cornea. 1999;18:538-543.
6. Holden BA, Sankaridurg PR, Sweeney DF, Stretton S, Naduvilath TJ, Rao GN. Microbial keratitis in prospective studies of extended wear with disposable hydrogel contact lenses. Cornea. 2005;24:156-161.
7. Keay L, Edwards K, Naduvilath T, et al. Microbial keratitis predisposing factors and morbidity. Ophthalmology. 2006;113:109-116.
8. Johnson AC, Heinzel FP, Diaconu E, et al. Activation of toll-like receptor (TLR)2, TLR4, and TLR9 in the mammalian cornea induces MyD88-dependent corneal inflammation. Invest Ophthalmol Vis Sci. 2005;46:589-595.
9. Khatri S, Lass JH, Heinzel FP, et al. Regulation of endotoxininduced keratitis by PECAM-1, MIP-2, and toll-like receptor 4. Invest Ophthalmol Vis Sci. 2002;43:2278-2284.
10. Schultz CL, Buret AG, Olson ME, Ceri H, Read RR, Morck DW. Lipopolysaccharide entry in the damaged cornea and specific uptake by polymorphonuclear neutrophils. Infect Immun. 2000;68:1731-1734.
11. Schultz CL, Morck DW, McKay SG, Olson ME, Buret A. Lipopolysaccharide induced acute red eye and corneal ulcers. Exp Eye Res. 1997;64:3-9.
12. Sun Y, Hise AG, Kalsow CM, Pearlman E. Staphylococcus aureusinduced corneal inflammation is dependent on Toll-like receptor 2 and myeloid differentiation factor 88. Infect Immun. 2006;74:5325-5332.
13. Lee MS, Kim YJ. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem. 2008;83:481-489.
14. Gioannini TL, Teghanemt A, Zhang D, et al. Isolation of an endotoxin-MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations. Proc Natl Acad Sci U S A. 2004;101:4186-4191.
15. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007;7:353-364.
16. Kutuzova GD, Albrecht RM, Erickson CM, Qureshi N. Diphosphoryl lipid A from Rhodobacter sphaeroides blocks the binding and internalization of lipopolysaccharide in RAW 264.7 cells. J Immunol. 2001;167:482-489.
17. Golenbock DT, Hampton RY, Qureshi N, Takayama K, Raetz CR. Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J Biol Chem. 1991;266:19490-19498.
18. Qureshi N, Takayama K, Kurtz R. Diphosphoryl lipid A obtained from the nontoxic lipopolysaccharide of Rhodopseudomonas sphaeroides is an endotoxin antagonist in mice. Infect Immun. 1991;59:441-444.
19. Rossignol DP, Lynn M. TLR4 antagonists for endotoxemia and beyond. Curr Opin Investig Drugs. 2005;6:496-502.
20. Hawkins LD, Christ WJ, Rossignol DP. Inhibition of endotoxin response by synthetic TLR4 antagonists. Curr Top Med Chem. 2004;4:1147-1171.
21. Rossignol DP, Lynn M. Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. J Endotoxin Res. 2002;8:483-488.
22. Savov JD, Brass DM, Lawson BL, McElvania-Tekippe E, Walker JK, Schwartz DA. Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide. Am J Physiol. 2005;289:L329-L337.
23. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007;29:467-509.
24. Bennett-Guerrero E, Grocott HP, Levy JH, et al. A phase II, doubleblind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass. Anesth Analg. 2007;104:378-383.
25. Rossignol DP, Wasan KM, Choo E, et al. Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers. Antimicrob Agents Chemother. 2004;48:3233-3240.
26. Kim HM, Park BS, Kim JI, et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell. 2007;130:906-917.
27. Kruszewski FH, Walker TL, DiPasquale LC. Evaluation of a human corneal epithelial cell line as an in vitro model for assessing ocular irritation. Fundam Appl Toxicol. 1997;36:130-140.
28. Ueta M, Nochi T, Jang MH, et al. Intracellularly expressed TLR2s and TLR4s contribution to an immunosilent environment at the ocular mucosal epithelium. J Immunol. 2004;173:3337-3347.
29. Lin M, Carlson E, Diaconu E, Pearlman E. CXCL1/KC and CXCL5/LIX are produced selectively by corneal fibroblasts and mediate neutrophil infiltration to the corneal stroma in LPS keratitis. J Leukoc Biol. 2007;81(3):786-792.
30. Adhikary G, Sun Y, Pearlman E. C-Jun NH2 terminal kinase (JNK) is an essential mediator of corneal inflammation induced by toll like receptor 2. 2008;83(4):991-997.
31. Visintin A, Halmen KA, Khan N, Monks BG, Golenbock DT, Lien E. MD-2 expression is not required for cell surface targeting of Tolllike receptor 4 (TLR4). J Leukoc Biol. 2006;80:1584-1592.
32. Shimamoto A, Chong AJ, Yada M, et al. Inhibition of toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation. 2006;114:I270-I274.
33. Zhou Z, Kozlowski J, Schuster DP. Physiologic, biochemical, and imaging characterization of acute lung injury in mice. Am J Respir Crit Care Med. 2005;172:344-351.
34. Johnson AC, Li X, Pearlman E. MyD88 functions as a negative regulator of TLR3/TRIF induced corneal inflammation by inhibiting activation of c-jun n-terminal kinase (JNK). J Biol Chem. 2008;283(7):3988-3996.
35. Zhang J, Xu K, Ambati B, Yu FS. Toll-like receptor 5-mediated corneal epithelial inflammatory responses to Pseudomonas aeruginosa flagellin. Invest Ophthalmol Vis Sci. 2003;44:4247-4254.
36. Kumar A, Zhang J, Yu FS. Toll-like receptor 3 agonist poly(I:C)-induced antiviral response in human corneal epithelial cells. Immunology. 2006;117:11-21.
37. Kumar A, Zhang J, Yu FS. Toll-like receptor 2-mediated expression of beta-defensin-2 in human corneal epithelial cells. Microbes Infect. 2006;8:380-389.
38. Nagai Y, Akashi S, Nagafuku M, et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol. 2002;3:667-672.
39. Yang KK, Dorner BG, Merkel U, et al. Neutrophil influx in response to a peritoneal infection with Salmonella is delayed in lipopolysaccharide-binding protein or CD14-deficient mice. J Immunol. 2002;169:4475-4480.
40. Czeslick E, Struppert A, Simm A, Sablotzki A. E5564 (Eritoran) inhibits lipopolysaccharide-induced cytokine production in human blood monocytes. Inflamm Res. 2006;55:511-515.
41. Song PI, Abraham TA, Park Y, et al. The expression of functional LPS receptor proteins CD14 and toll-like receptor 4 in human corneal cells. Invest Ophthalmol Vis Sci. 2001;42:2867-2877.
42. Blais DR, Vascotto SG, Griffith M, Altosaar I. LBP and CD14 secreted in tears by the lacrimal glands modulate the LPS response of corneal epithelial cells. Invest Ophthalmol Vis Sci. 2005;46:4235-4244.
43. Huang X, Du W, McClellan SA, Barrett RP, Hazlett LD. TLR4 is required for host resistance in Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci. 2006;47:4910-4916.
44. Sun Y, Fox T, Adhikary G, Kester M, Pearlman E. Inhibition of corneal inflammation by liposomal delivery of short-chain, C-6 ceramide. J Leukoc Biol. 2008;83:1512-1521.